Castle Biosciences (CSTL) Profit After Tax (2018 - 2026)

Castle Biosciences has reported Profit After Tax for 9 years, with the latest figure at -$2.1 million in Q2 2026.

• Quarterly Profit After Tax fell 145.54% year-over-year to -$2.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$19.4 million (down 105.1% YoY) and the FY2025 annual result came in at -$24.2 million, down 232.41% from the prior year.
• Profit After Tax climbed to -$2.1 million in Q2 2026 per CSTL's latest filing, from -$14.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at $9.6 million in Q4 2024 and troughed at -$29.2 million in Q1 2023.
• A 5-year average of -$8.2 million and a median of -$2.6 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax slumped 1039.38% in 2023, then surged 471.71% in 2024.
• Over 5 years, Profit After Tax stood at -$20.6 million in 2022, then jumped by 87.49% to -$2.6 million in 2023, then soared by 471.71% to $9.6 million in 2024, then sank by 124.32% to -$2.3 million in 2025, then increased by 11.66% to -$2.1 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.1 million, -$14.5 million, and -$2.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.